credentis presented in cooperation with the ZHAW and the University of Zurich at the Swiss MedTech Day 2016 the first, very promising in-vitro data for the treatment of periodontal defects with the patented CUROLOX® TECHNOLOGY.
Supported by the CTI, the project team developed a tissue engineering model mimicking a periodontal defect for testing of the different candidates of the CUROLOX® TECHNOLOGY library.
“The development of this model is in-line with the current trend for in vitro models and shows its enormous potential for predicting the effectiveness of a product. At the same time it allows us to expand our expertise of three-dimensional soft tissue cultures such as the skin to the periodontium” says Dr. Stephanie Mathes, Section Head of Tissue Engineering at ZHAW Wädenswil.
The goal of the project is to use CUROLOX® TECHNOLOGY as scaffold for the regeneration of soft and hard tissue in periodontal defects. “This in-vitro model allows us, the existing CUROLOX® TECHNOLOGY Library in a fast and efficient way to screen for the best candidate- the first promising candidates have already been identified” says Michael Hug, CTO of credentis ag.
Poster CUROLOX® TECHNOLOGY and Periodontal Regeneration
About credentis ag
credentis ag is headquartered in Windisch, Switzerland. credentis has won multiple awards as well as support from organizations such as Genilem. Public grants include Swiss National Science Foundation (SNF), CTI-Projects, Aargauer Forschungsfonds an the Medical Technologies IKC (in co-operation with the University of Leeds).
Dr. Dominik Lysek, CEO and Michael Hug, CTO have a strong track record in science, development and medical technology, with focus in the dental industry. credentis board members Dr. Werner Berner, Dr. Michael Peetz, Gerard Moufflet and Dr. Erich Platzer (chairman), contribute their pharma, medtech and dental industry expertise.
